Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules (苁蓉舒痉颗粒) in Patients with Parkinson’s Disease and Syndrome of Shen (Kidney) Essence Deficiency

2020 ◽  
Vol 26 (6) ◽  
pp. 412-419
Author(s):  
Shi-ya Chen ◽  
Shao-jian Xiao ◽  
You-ning Lin ◽  
Xi-yu Li ◽  
Qian Xu ◽  
...  
2016 ◽  
Vol 23 (10) ◽  
pp. 893-894 ◽  
Author(s):  
Takeya Kitta ◽  
Ichiro Yabe ◽  
Ikuko Takahashi ◽  
Masaaki Matsushima ◽  
Hidenao Sasaki ◽  
...  

2009 ◽  
Vol 4 (2) ◽  
pp. 24
Author(s):  
Santiago Perez Lloret ◽  
Olivier Rascol ◽  
◽  

Background: Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch is approved by the regulatory authorities for use in all stages of Parkinson’s disease (PD) in Europe and for early-stage PD in the US. For patients with advanced-stage PD and motor fluctuations, approved doses range from 4mg/24 hours to 16mg/24 hours. The rotigotine patch offers a certain number of potential advantages, including faster onset as intestinal absorption is not needed, continuous drug delivery and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is continuous drug delivery, which may avoid the pulsatile dopaminergic stimulation that has been postulated to be related to the development of motor complications.Objective: The aim of this article is to review the pharmacokinetics, pharmacodynamics and clinical efficacy and tolerability of the rotigotine transdermal patch.Methods: Source material was identified using a PubMed search for the term ‘rotigotine’ in articles published up to October 2009 and a review of published congress abstracts. The review focused primarily on publications related to the rotigotine indication for advanced PD.Results and conclusions: The rotigotine transdermal patch demonstrates clinical efficacy and a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists, except for local skin reactions, which are common with the rotigotine patch. The once-daily patch formulation may encourage compliance; however, as is the case for other theoretical advantages of continuous drug delivery, such as reduced emergence of motor complications and improved tolerance of peripheral adverse events, this requires further detailed study.


1992 ◽  
Vol 94 (3) ◽  
pp. 205-211 ◽  
Author(s):  
E.C. Wolters ◽  
M.W.I.M. Horstink ◽  
R.A.C. Roos ◽  
E.N.H. Jansen

1991 ◽  
Vol 41 (5) ◽  
pp. 493-494 ◽  
Author(s):  
F. Durif ◽  
E. Jeanneau ◽  
F. Serre-Debeauvais ◽  
D. Deffond ◽  
A. Eschalier ◽  
...  

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kun-Peng Li ◽  
Zong-Lei Zhou ◽  
Ru-Zhen Zhou ◽  
Yan Zhu ◽  
Zeng-Qiao Zhang

Abstract Background Progression of freezing of gait, a common pathological gait in Parkinson’s disease, is an important risk factor for diagnosing the disease and has been shown to predispose patients to easy falls, loss of independent living ability, and reduced quality of life. Treating Parkinson’s disease with freezing of gait is very difficult, while the use of medicine and operation has been ineffective. Music exercise therapy, which entails listening to music as you exercise, has been proposed as a treatment technology that can change patients’ behavior, emotions, and physiological activity. In recent years, music exercise therapy has been widely used in treatment of motor disorders and neurological diseases and achieved remarkable results. Results from our earlier pilot study revealed that music exercise therapy can improve the freezing of gait of Parkinson’s patients and improve their quality of life. Therefore, we aim to validate clinical efficacy of this therapy on freezing of gait of Parkinson’s patients using a larger sample size. Methods/design This three-arm randomized controlled trial will evaluate clinical efficacy of music exercise therapy in improving the freezing of gait in Parkinson’s patients. We will recruit a total of 81 inpatients with Parkinson’s disease, who meet the trial criteria. The patients will randomly receive music exercise with and without music as well as routine rehabilitation therapies, followed by analysis of changes in their gait and limb motor function after 4 weeks of intervention. We will first use a three-dimensional gait analysis system to evaluate changes in patients’ gait, followed by assessment of their limb function, activity of daily living and fall risk. Discussion The findings of this trial are expected to affirm the clinical application of this therapy for future management of the disease. Trial registration Chinese Clinical Trial Registry ChiCTR1900026063. Registered on September 20, 2019


Sign in / Sign up

Export Citation Format

Share Document